Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$11.42 USD

11.42
1,455,027

-0.34 (-2.89%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $11.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

by Zacks Equity Research

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.

Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Collegium (COLL) Shares Rise on Financial Outlook for 2024

by Zacks Equity Research

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

by Zacks Equity Research

C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

by Zacks Equity Research

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

by Zacks Equity Research

Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

by Zacks Equity Research

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

by Zacks Equity Research

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.

Ekta Bagri headshot

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

by Zacks Equity Research

Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

by Zacks Equity Research

NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.

Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data

by Zacks Equity Research

Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

by Zacks Equity Research

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

by Zacks Equity Research

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 91.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How

by Zacks Equity Research

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

by Zacks Equity Research

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.